UGRO Capital Q1FY27: consolidated PAT ₹67.87 Cr, but underlying PBT growth near-flat

UGRO Capital's consolidated Q1FY27 (quarter ended June 30, 2026) print headlines well — revenue from operations of ₹496.94 Cr and PAT of ₹67.87 Cr, up 32.8% QoQ and a nominal 98.8% YoY against the ₹34.13 Cr standalone base reported a year ago, before the Profectus Capital and Grox Technologies acquisitions were consolidated. On a like-for-like standalone (parent-only) basis, PAT was ₹60.71 Cr on revenue of ₹417.41 Cr, up just 0.82% YoY at the revenue line. Consolidated basic EPS was ₹4.44 versus ₹3.35 in Q4FY26; standalone basic EPS was ₹3.97 versus ₹1.94 in Q4FY26 and ₹3.61 a year ago. No management press release has been extracted for this filing, so there is no company framing to cross-check against the numbers beyond the regulatory filing itself. The reported profit jump is not an operating story. Standalone pre-tax profit (PBT) was ₹48.66 Cr, up just 1.02% YoY from ₹48.17 Cr — essentially flat — and consolidated PBT of ₹61.54 Cr was actually down 13.6% QoQ from ₹71.24 Cr in Q4FY26. What moved PAT was the tax line: the company opted into the concessional tax regime under the new Income-tax Act, 2025 (Section 200), cutting its corporate rate from 29.12% to 25.17% (note 11), and the resulting deferred-tax remeasurement flipped standalone tax expense to a ₹12.05 Cr credit (versus a ₹14.04 Cr charge a year ago) and consolidated tax to a ₹6.33 Cr credit. Strip this one-off out and use PBT as the organic yardstick, and adjusted YoY PAT growth is roughly +1%, not the +98.8% headline. Standalone net profit margin of 13.37% (Q4: 5.80%, year-ago: 8.09%) reflects this tax swing rather than operating margin expansion. Consolidated revenue fell 18.1% QoQ to ₹496.94 Cr from ₹606.57 Cr, driven mainly by a drop in net gain on derecognition of financial instruments (loan assignment/securitisation income) to ₹74.87 Cr from ₹154.59 Cr in Q4FY26 — a deal-timing-dependent line for an NBFC that actively co-lends and assigns loans. No quarter-specific Street consensus could be confirmed for this print; general pre-result commentary pointed to ~15-20% full-year FY27 PAT growth expectations, but no single-quarter estimate was found, so vsStreet is marked unknown. Against management's prior guidance — a transitional FY27 with flattish AUM as the prime intermediated book is run down 15-20% annually while Emerging Market LAP and Embedded Finance are scaled, no incremental equity raises through FY29, and a target cash-led ROA of 3.0-3.5% by FY29 — this quarter's roughly flat organic revenue and profit fits the 'transitional, flattish' framing directionally, though this filing carries no AUM breakdown, so the LAP/Embedded-Finance mix shift and ROA trajectory specifically could not be verified from the P&L alone. Asset quality improved sequentially: standalone Gross Stage 3 fell to 2.75% from 3.66% in Q4FY26 (year-ago: 2.66%) and Net Stage 3 to 1.71% from 2.24% (year-ago: 1.49%) — better than last quarter but still above the year-ago level. Leverage kept building, with standalone Debt-Equity at 3.33x (Q4: 3.24x, year-ago: 3.13x) and consolidated capital adequacy easing to 20.96% from 21.17% in Q4FY26. Corporate activity this quarter included the NCLT filing (July 16, 2026) for the Profectus amalgamation scheme, now reserved for pronouncement after the July 24 hearing, and continued commercial paper issuance (₹28.79 Cr and ₹19.15 Cr) for funding — both routine financing-business items rather than P&L-moving developments this quarter.